These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23886457)

  • 1. [Public clinical trials: which kind of monitoring should be used?].
    Cornu C; Binquet C; Thalamas C; Vigouroux C; Gaillard S; Ginhoux T; Vaz B; Jossan C; Félin A; Sailly A; Gueyffier F; Journot V; Kassaï B
    Therapie; 2013; 68(3):135-41. PubMed ID: 23886457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panel discussion 2.
    Lan G; Lindborg S; Neaton J
    Clin Trials; 2012 Dec; 9(6):736-40. PubMed ID: 23250944
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O; Houben P; Ihrig K; Ohmann C; Paulus U; Pfistner B; Schwarz G; Strenge-Hesse A; Zettelmeyer U
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus adaptive monitoring procedures: A commentary.
    Fleming TR
    Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A statistical approach to central monitoring of data quality in clinical trials.
    Venet D; Doffagne E; Burzykowski T; Beckers F; Tellier Y; Genevois-Marlin E; Becker U; Bee V; Wilson V; Legrand C; Buyse M
    Clin Trials; 2012 Dec; 9(6):705-13. PubMed ID: 22684241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and interpretation of data obtained from clinical trials in pain management.
    Theodore BR; Gatchel RJ
    Pain Pract; 2008; 8(6):461-72. PubMed ID: 19000174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.
    Brosteanu O; Schwarz G; Houben P; Paulus U; Strenge-Hesse A; Zettelmeyer U; Schneider A; Hasenclever D
    Clin Trials; 2017 Dec; 14(6):584-596. PubMed ID: 28786330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, operation, and interpretation of clinical trials.
    Pihlstrom BL; Barnett ML
    J Dent Res; 2010 Aug; 89(8):759-72. PubMed ID: 20581353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
    O'Neill RT; Temple R
    Clin Pharmacol Ther; 2012 Mar; 91(3):550-4. PubMed ID: 22318615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple comparisons in complex clinical trial designs.
    Hung HM; Wang SJ
    Biom J; 2013 May; 55(3):420-9. PubMed ID: 23620458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive methods: when and how should they be used in clinical trials?
    Porcher R; Lecocq B; Vray M;
    Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proceedings of the University of Pennsylvania annual conference on statistical issues in clinical trials: emerging statistical issues in the conduct and monitoring of clinical trials.
    Ellenberg JH; Ellenberg SS
    Clin Trials; 2012 Dec; 9(6):669-70. PubMed ID: 23250941
    [No Abstract]   [Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
    Fleishman AN; Parker RA
    J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.